Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 63

Results For "ANDA"

2593 News Found

Revvity launches reagent technology for targeted therapeutics
News | August 06, 2025

Revvity launches reagent technology for targeted therapeutics

Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research


Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr
News | August 02, 2025

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter


Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India
News | August 02, 2025

Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India

The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements


Fermenta receives CEP by EDQM for Vitadee 100 SD
Biotech | August 01, 2025

Fermenta receives CEP by EDQM for Vitadee 100 SD

Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3


iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025
News | August 01, 2025

iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025

A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide


Novartis India posts Q1 FY26 net profit at Rs. 27.62 Cr
News | July 30, 2025

Novartis India posts Q1 FY26 net profit at Rs. 27.62 Cr

Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025


Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries
Opinion | July 28, 2025

Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries

The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production


Akums’ Haridwar factory receives ANVISA GMP certification for sterile manufacturing plant
Drug Approval | July 28, 2025

Akums’ Haridwar factory receives ANVISA GMP certification for sterile manufacturing plant

This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms